Cidara Therapeutics, Inc. (CDTX)
NASDAQ: CDTX · Real-Time Price · USD
20.40
+2.95 (16.91%)
At close: Nov 22, 2024, 4:00 PM
21.99
+1.59 (7.79%)
After-hours: Nov 22, 2024, 5:45 PM EST
Cidara Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 44.65 | 63.91 | 64.45 | 49.57 | 12.07 | 20.92 | Upgrade
|
| Revenue Growth (YoY) | 44.48% | -0.84% | 30.01% | 310.81% | -42.30% | - | Upgrade
|
| Cost of Revenue | 66.31 | 70.06 | 77.41 | 73.09 | 68.02 | 46.4 | Upgrade
|
| Gross Profit | -21.65 | -6.15 | -12.96 | -23.52 | -55.95 | -25.49 | Upgrade
|
| Selling, General & Admin | 21.51 | 18.33 | 20.55 | 18.74 | 15.9 | 16.24 | Upgrade
|
| Operating Expenses | 21.51 | 18.33 | 20.55 | 18.74 | 15.9 | 16.24 | Upgrade
|
| Operating Income | -43.16 | -24.48 | -33.5 | -42.26 | -71.85 | -41.72 | Upgrade
|
| Interest Expense | - | - | - | -0.21 | -0.26 | - | Upgrade
|
| Interest & Investment Income | 4.53 | 2 | 0.19 | - | - | 0.22 | Upgrade
|
| EBT Excluding Unusual Items | -38.64 | -22.49 | -33.31 | -42.47 | -72.11 | -41.5 | Upgrade
|
| Other Unusual Items | - | - | - | - | - | 0.41 | Upgrade
|
| Pretax Income | -123.52 | -22.49 | -33.31 | -42.47 | -72.11 | -41.09 | Upgrade
|
| Income Tax Expense | 0.44 | 0.44 | 0.27 | - | - | - | Upgrade
|
| Net Income | -120.73 | -22.93 | -33.58 | -42.47 | -72.11 | -41.09 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | 2.76 | - | Upgrade
|
| Net Income to Common | -120.73 | -22.93 | -33.58 | -42.47 | -74.87 | -41.09 | Upgrade
|
| Shares Outstanding (Basic) | 5 | 4 | 3 | 3 | 2 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 5 | 4 | 3 | 3 | 2 | 1 | Upgrade
|
| Shares Change (YoY) | 21.86% | 25.15% | 33.18% | 26.22% | 38.83% | 15.71% | Upgrade
|
| EPS (Basic) | -23.94 | -5.25 | -9.61 | -16.19 | -36.03 | -27.45 | Upgrade
|
| EPS (Diluted) | -23.94 | -5.25 | -9.61 | -16.20 | -36.03 | -27.45 | Upgrade
|
| Free Cash Flow | -160.15 | -22.94 | -28.59 | -25.27 | -54.6 | -28.57 | Upgrade
|
| Free Cash Flow Per Share | -31.75 | -5.25 | -8.19 | -9.64 | -26.28 | -19.09 | Upgrade
|
| Gross Margin | -48.49% | -9.62% | -20.10% | -47.44% | - | -121.86% | Upgrade
|
| Operating Margin | -96.66% | -38.31% | -51.98% | -85.24% | -595.42% | -199.49% | Upgrade
|
| Profit Margin | -270.38% | -35.88% | -52.11% | -85.67% | -620.48% | -196.47% | Upgrade
|
| Free Cash Flow Margin | -358.65% | -35.89% | -44.36% | -50.98% | -452.45% | -136.59% | Upgrade
|
| EBITDA | -43.01 | -24.37 | -33.36 | -42.07 | -71.56 | -41.4 | Upgrade
|
| EBITDA Margin | -96.33% | -38.14% | -51.76% | -84.86% | - | -197.92% | Upgrade
|
| D&A For EBITDA | 0.15 | 0.11 | 0.14 | 0.19 | 0.29 | 0.33 | Upgrade
|
| EBIT | -43.16 | -24.48 | -33.5 | -42.26 | -71.85 | -41.72 | Upgrade
|
| EBIT Margin | -96.66% | -38.31% | -51.98% | -85.24% | - | -199.49% | Upgrade
|
| Revenue as Reported | 44.65 | 63.91 | 64.45 | 49.57 | 12.07 | 20.92 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.